Serina Therapeutics Shares Jump After FDA Clears IND for SER-252 Parkinson’s Program
Serina Therapeutics saw its stock surge after the U.S. FDA cleared an Investigational New Drug application for SER-252, enabling the company to proceed with site-level activities for a planned Phase 1b registrational trial. The firm has also initiated site start-up and regulatory steps in Australia to support a global registrational program, and sa…